Longitudinal Plasma Biomarker Profiles Predict Neurological Outcome in Traumatic Spinal Cord Injury
Authors:
- 5 February 2025
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 97 (6) , 1180-1189
Abstract
Objective: Traumatic spinal cord injury (SCI) is diagnosed by imaging and clinical scoring using the American Spinal Injury Association Impairment Scale (AIS). These methods have limited value for prognosis. Here, the prognostic value of plasma neurofilament‐light (NfL), glial fibrillary acidic protein (GFAP), and contactin‐1 (CNTN‐1) was analyzed.Methods: Biomarker levels were determined in the plasma of traumatic SCI patients (n = 37) and healthy controls (n = 22). SCI samples (n = 112) were collected at different time points from 0 to 4 days to 18 weeks post‐injury. NfL and GFAP were measured by single molecule array (Simoa) technology, CNTN‐1 by Luminex. Baseline and outcome AIS and motor scores were collected as a measure of injury severity.Results: NfL, GFAP, and CNTN‐1 showed different kinetics in SCI patients over time. Baseline biomarker levels could identify AIS‐A SCI patients (NfL + GFAP) and discriminate between patients with a motor score change <5 and those with a change ≥5 (NfL + GFAP+CNTN‐1). Longitudinally, NfL could identify AIS‐A patients up to 12 weeks post‐SCI and discriminate between patients with a motor score change <5 and those with a change ≥5 up to 18 weeks post‐SCI. Further, baseline biomarker levels positively (NfL + GFAP) or negatively (CNTN‐1) correlated with outcome injury severity and together could accurately predict AIS conversion (AUC 0.863) and motor score change (AUC 0.857). This predictive ability was maintained in subacute/chronic SCI stages.Interpretation: In conclusion, plasma NfL, GFAP, and CNTN‐1 are potential prognostic biomarkers in SCI. This is important for patient stratification in clinical trials, prediction of neurological outcome and informed decision‐making in SCI treatment and rehabilitation. ANN NEUROL 2025;97:1180–1189Keywords
Funding Information
- Wings for Life (WFL‐BE‐20/20)
This publication has 28 references indexed in Scilit:
- Blood GFAP as an emerging biomarker in brain and spinal cord disordersNature Reviews Neurology, 2022
- Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathologyAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022
- Updates of the International Standards for Neurologic Classification of Spinal Cord InjuryPhysical Medicine and Rehabilitation Clinics of North America, 2020
- Cerebrospinal fluid levels of GFAP and pNF-H are elevated in patients with chronic spinal cord injury and neurological deteriorationActa Neurochirurgica, 2020
- Serum neurofilament light levels in normal aging and their association with morphologic brain changesNature Communications, 2020
- Neurofilaments as biomarkers in neurological disordersNature Reviews Neurology, 2018
- TraumaSurgical Clinics of North America, 2017
- Traumatic spinal cord injuryNature Reviews Disease Primers, 2017
- New movements in neurofilament transport, turnover and diseaseExperimental Cell Research, 2007
- The International Standards Booklet for Neurological and Functional Classification of Spinal Cord InjurySpinal Cord, 1994